In the long effort to make cancer visible before it becomes untreatable, a first-in-human trial presented at the 2026 Society of Nuclear Medicine and Molecular Imaging meeting has offered a new way of seeing. Researchers at the University of California, San Francisco tested a radioactive imaging agent that seeks out a protein called CD46 on prostate cancer cells — a target that persists even when other molecular markers fade — and found it revealed far more disease than conventional scans. For men with the most resistant form of prostate cancer, the ability to see what was previously hidden is
UroToday
· Jun 02, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Novel CD46-Targeted PET Imaging Shows Promise in Metastatic Prostate Cancer
◉
Health & Medicine
8293 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Baylor launches trial of Eli Lilly antibody effective against all know…
The Dallas Morning News · 99% coincidencia
Doctors Debunk 7 Dangerous Health Myths Indians Still Believe
TheHealthSite · 99% coincidencia
mRNA vaccines safe, effective; cancer treatment potential next frontie…
CBC · 99% coincidencia
Lecanemab for Alzheimer's: Modest Benefits Demand Careful Patient Disc…
Medical Xpress · 99% coincidencia
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Sesgo y Encuadre
⚖
Medical trade publication reports on promising early-stage imaging technology with neutral, evidence-focused language and standard clinical trial framing.
Bias Direction
center
Confidence
HIGH
Standard medical conference reporting with emphasis on clinical trial methodology, safety data, and technical specifications. Uses conventional academic/clinical framing with progressive disclosure of study design and results.
promising preclinical therapeutic efficacy
encouraging preliminary activity
superior lesion detection
Cost-effectiveness or economic analysis
Patient experience or quality-of-life considerations
Comparative effectiveness vs. existing PSMA-based imaging in clinical practice
Limitations or potential drawbacks of the technology
Timeline to clinical availability
Perspectives from competing research groups or alternative approaches
Impacto Geopolítico
🌎
Medical imaging breakthrough in prostate cancer detection has no direct geopolitical implications; this is a clinical research advancement with potential healthcare applications.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Novel CD46-targeted PET imaging shows promise for detecting metastatic prostate cancer with superior sensitivity, potentially expanding diagnostic imaging market and supporting development of companion diagnostics.
Market Signal
bullish
Confidence
MED
Medical Devices & Diagnostics
Pharmaceutical Manufacturing
Healthcare Services
Nuclear Medicine
Oncology
Patients with metastatic prostate cancer may gain access to more accurate diagnostic imaging, potentially enabling earlier detection of metastases and improved treatment planning, though costs and insurance coverage remain uncertain.
FDA may expedite approval pathways for companion diagnostics; CMS will need to establish reimbursement codes and coverage policies for novel PET imaging agents; regulatory frameworks for radiopharmaceutical manufacturing may require updates.